Rituximab vs placeboPalpebral aperture change · thyroid‐associated ophthalmopathy1 finding from 1 reviewRituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 25 participantsVery low